Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma?

Research output: Contribution to journal › Review › Research › peer-review

Standard

Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma? / Mouhammad, Zaynab Ahmad; Vohra, Rupali; Horwitz, Anna; Thein, Anna Sophie; Rovelt, Jens; Cvenkel, Barbara; Williams, Pete A.; Azuara-Blanco, Augusto; Kolko, Miriam.

In: Frontiers in Neuroscience, Vol. 16, 824054, 2022.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Mouhammad, ZA, Vohra, R, Horwitz, A, Thein, AS, Rovelt, J, Cvenkel, B, Williams, PA, Azuara-Blanco, A & Kolko, M 2022, 'Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma?', Frontiers in Neuroscience, vol. 16, 824054. https://doi.org/10.3389/fnins.2022.824054

APA

Mouhammad, Z. A., Vohra, R., Horwitz, A., Thein, A. S., Rovelt, J., Cvenkel, B., Williams, P. A., Azuara-Blanco, A., & Kolko, M. (2022). Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma? Frontiers in Neuroscience, 16, [824054]. https://doi.org/10.3389/fnins.2022.824054

Vancouver

Mouhammad ZA, Vohra R, Horwitz A, Thein AS, Rovelt J, Cvenkel B et al. Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma? Frontiers in Neuroscience. 2022;16. 824054. https://doi.org/10.3389/fnins.2022.824054

Author

Mouhammad, Zaynab Ahmad ; Vohra, Rupali ; Horwitz, Anna ; Thein, Anna Sophie ; Rovelt, Jens ; Cvenkel, Barbara ; Williams, Pete A. ; Azuara-Blanco, Augusto ; Kolko, Miriam. / Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma?. In: Frontiers in Neuroscience. 2022 ; Vol. 16.

Bibtex

@article{0c6fdf1c4d654223a8a462a7bb4b3c34,
title = "Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma?",
abstract = "Glaucoma is a common ocular neurodegenerative disease characterized by the progressive loss of retinal ganglion cells and their axons. It is the most common cause of irreversible blindness. With an increasing number of glaucoma patients and disease progression despite treatment, it is paramount to develop new and effective therapeutics. Emerging new candidates are the receptor agonists of the incretin hormone glucagon-like-peptide-1 (GLP-1), originally used for the treatment of diabetes. GLP-1 receptor (GLP-1R) agonists have shown neuroprotective effects in preclinical and clinical studies on neurodegenerative diseases in both the brain (e.g., Alzheimer{\textquoteright}s disease, Parkinson{\textquoteright}s disease, stroke and diabetic neuropathy) and the eye (e.g., diabetic retinopathy and AMD). However, there are currently very few studies investigating the protective effects of GLP-1R agonists in the treatment of specifically glaucoma. Based on a literature search on PubMed, the Cochrane Library, and ClinicalTrials.gov, this review aims to summarize current clinical literature on GLP-1 receptor agonists in the treatment of neurodegenerative diseases to elucidate their potential in future anti-glaucomatous treatment strategies.",
keywords = "antidiabtics, glaucoma, GLP-1 receptor agonists, neurodegenerative diseases, neuroprotection, ophthalmology",
author = "Mouhammad, {Zaynab Ahmad} and Rupali Vohra and Anna Horwitz and Thein, {Anna Sophie} and Jens Rovelt and Barbara Cvenkel and Williams, {Pete A.} and Augusto Azuara-Blanco and Miriam Kolko",
note = "Funding Information: This work was supported by Mauritzen La Fontaine Familiefond, the BRIDGE ? Translational Excellence Programme funded by the Novo Nordisk Foundation (Grant agreement no. NNF18SA0034956). PW was supported by Karolinska Institutet in the form of a Board of Research Faculty Funded Career Position and by St. Erik Eye Hospital philanthropic donations, Vetenskapsr?det 2018-02124. Publisher Copyright: Copyright {\textcopyright} 2022 Mouhammad, Vohra, Horwitz, Thein, Rovelt, Cvenkel, Williams, Azuara-Blanco and Kolko.",
year = "2022",
doi = "10.3389/fnins.2022.824054",
language = "English",
volume = "16",
journal = "Frontiers in Neuroscience",
issn = "1662-4548",
publisher = "Frontiers Research Foundation",

}

RIS

TY - JOUR

T1 - Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma?

AU - Mouhammad, Zaynab Ahmad

AU - Vohra, Rupali

AU - Horwitz, Anna

AU - Thein, Anna Sophie

AU - Rovelt, Jens

AU - Cvenkel, Barbara

AU - Williams, Pete A.

AU - Azuara-Blanco, Augusto

AU - Kolko, Miriam

N1 - Funding Information: This work was supported by Mauritzen La Fontaine Familiefond, the BRIDGE ? Translational Excellence Programme funded by the Novo Nordisk Foundation (Grant agreement no. NNF18SA0034956). PW was supported by Karolinska Institutet in the form of a Board of Research Faculty Funded Career Position and by St. Erik Eye Hospital philanthropic donations, Vetenskapsr?det 2018-02124. Publisher Copyright: Copyright © 2022 Mouhammad, Vohra, Horwitz, Thein, Rovelt, Cvenkel, Williams, Azuara-Blanco and Kolko.

PY - 2022

Y1 - 2022

N2 - Glaucoma is a common ocular neurodegenerative disease characterized by the progressive loss of retinal ganglion cells and their axons. It is the most common cause of irreversible blindness. With an increasing number of glaucoma patients and disease progression despite treatment, it is paramount to develop new and effective therapeutics. Emerging new candidates are the receptor agonists of the incretin hormone glucagon-like-peptide-1 (GLP-1), originally used for the treatment of diabetes. GLP-1 receptor (GLP-1R) agonists have shown neuroprotective effects in preclinical and clinical studies on neurodegenerative diseases in both the brain (e.g., Alzheimer’s disease, Parkinson’s disease, stroke and diabetic neuropathy) and the eye (e.g., diabetic retinopathy and AMD). However, there are currently very few studies investigating the protective effects of GLP-1R agonists in the treatment of specifically glaucoma. Based on a literature search on PubMed, the Cochrane Library, and ClinicalTrials.gov, this review aims to summarize current clinical literature on GLP-1 receptor agonists in the treatment of neurodegenerative diseases to elucidate their potential in future anti-glaucomatous treatment strategies.

AB - Glaucoma is a common ocular neurodegenerative disease characterized by the progressive loss of retinal ganglion cells and their axons. It is the most common cause of irreversible blindness. With an increasing number of glaucoma patients and disease progression despite treatment, it is paramount to develop new and effective therapeutics. Emerging new candidates are the receptor agonists of the incretin hormone glucagon-like-peptide-1 (GLP-1), originally used for the treatment of diabetes. GLP-1 receptor (GLP-1R) agonists have shown neuroprotective effects in preclinical and clinical studies on neurodegenerative diseases in both the brain (e.g., Alzheimer’s disease, Parkinson’s disease, stroke and diabetic neuropathy) and the eye (e.g., diabetic retinopathy and AMD). However, there are currently very few studies investigating the protective effects of GLP-1R agonists in the treatment of specifically glaucoma. Based on a literature search on PubMed, the Cochrane Library, and ClinicalTrials.gov, this review aims to summarize current clinical literature on GLP-1 receptor agonists in the treatment of neurodegenerative diseases to elucidate their potential in future anti-glaucomatous treatment strategies.

KW - antidiabtics

KW - glaucoma

KW - GLP-1 receptor agonists

KW - neurodegenerative diseases

KW - neuroprotection

KW - ophthalmology

U2 - 10.3389/fnins.2022.824054

DO - 10.3389/fnins.2022.824054

M3 - Review

C2 - 35264926

AN - SCOPUS:85125848004

VL - 16

JO - Frontiers in Neuroscience

JF - Frontiers in Neuroscience

SN - 1662-4548

M1 - 824054

ER -

ID: 300333359